Want to see SBFM full AI Analyst Report?
Top Page
Sunshine Biopharma
(NASDAQ:SBFM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.00
▼(-39.76% Downside)
Action:Reiterated
Date:08/17/26
The score is pulled down primarily by weak financial performance (sharp TTM revenue decline, ongoing losses, and continued negative/free cash flow deterioration). Technicals also weigh heavily, with a clear downtrend below major moving averages and negative MACD, despite oversold readings. Valuation is only slightly supportive because the negative P/E reflects ongoing losses and there is no dividend yield to offset risk.
Positive Factors
Low Financial Leverage
Very low leverage limits interest-burden pressure and reduces refinancing risk. This gives Sunshine Biopharma greater financial flexibility than a highly indebted peer while it works to improve earnings and cash generation.
Negative Factors
Persistent Revenue and Profitability Weakness
The sharp revenue decline and continuing net losses indicate that commercialization momentum and operating scale remain unproven. Sustained weakness could limit investment capacity and make the company’s growth strategy harder to execute.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low leverage limits interest-burden pressure and reduces refinancing risk. This gives Sunshine Biopharma greater financial flexibility than a highly indebted peer while it works to improve earnings and cash generation.
Read all positive factors
Sunshine Biopharma (SBFM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.50M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue Growth-2.74%
EPS Growth60.85%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-10.15
Shares Outstanding3,877,337
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.40M
Sunshine Biopharma Business Overview & Revenue Model
Company Description
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-dif...
How the Company Makes Money
Sunshine Biopharma makes money primarily through pharmaceutical product revenue—selling drugs it commercializes (including generic pharmaceutical products) into the market through established distribution and sales channels. Its revenue model can ...
Sunshine Biopharma Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
64
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.35M | 36.31M | 34.87M | 24.09M | 4.35M | 228.43K |
| Gross Profit | 10.53M | 11.92M | 10.67M | 8.34M | 1.70M | 110.60K |
| EBITDA | -5.26M | -5.62M | -5.14M | -3.82M | -26.45M | -12.09M |
| Net Income | -5.83M | -5.98M | -5.13M | -4.51M | -26.74M | -12.44M |
Balance Sheet | ||||||
| Total Assets | 33.63M | 30.08M | 30.56M | 27.35M | 29.55M | 2.20M |
| Cash, Cash Equivalents and Short-Term Investments | 13.75M | 9.12M | 9.69M | 16.29M | 21.83M | 2.05M |
| Total Debt | 678.34K | 812.42K | 952.48K | 657.71K | 765.26K | 1.90M |
| Total Liabilities | 6.09M | 7.04M | 7.06M | 6.14M | 7.92M | 1.99M |
| Stockholders Equity | 27.54M | 23.04M | 23.50M | 21.21M | 21.63M | 211.66K |
Cash Flow | ||||||
| Free Cash Flow | -4.60M | -5.51M | -14.85M | -9.56M | -5.55M | -1.83M |
| Operating Cash Flow | -5.33M | -5.33M | -12.53M | -8.78M | -5.25M | -1.83M |
| Investing Cash Flow | -278.14K | -836.31K | -2.32M | -656.15K | -14.62M | 0.00 |
| Financing Cash Flow | 8.60M | 4.75M | 9.29M | 3.43M | 39.47M | 2.90M |
Sunshine Biopharma Technical Analysis
Negative
1.66
Price Trends
1.73
Negative
4.74
Negative
8.88
Negative
Market Momentum
-0.23
Negative
30.37
Neutral
36.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.73, and below the 200-day MA of 8.88, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 30.37 is Neutral, neither overbought nor oversold. The STOCH value of 36.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.
Sunshine Biopharma Risk Analysis
Sunshine Biopharma disclosed 32 risk factors in its most recent earnings report. Sunshine Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted Q4, 2023
Sunshine Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $6.42M | -1.10 | -88.38% | ― | 47.00% | 50.49% | |
44 Neutral | $5.66M | -1.66 | -33.59% | ― | 10.01% | 95.01% | |
43 Neutral | $4.50M | -0.11 | -25.58% | ― | -2.74% | 60.85% | |
37 Underperform | $1.03M | -1,062.50 | -3.03% | ― | -11.91% | -285.23% | |
32 Underperform | $2.36M | -0.06 | -408.33% | ― | ― | 92.53% |
* Healthcare Sector Average
SBFM
Sunshine Biopharma
1.16
-12.84
-91.71%
SNOA
Sonoma Pharmaceuticals
1.34
-3.75
-73.67%
YCBD
cbdMD
0.51
-0.16
-24.18%
IMCC
IM Cannabis Corp
0.11
-2.20
-95.15%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.76
-30.63
-89.07%
Sunshine Biopharma Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Adjusts Series B Warrant Terms
Neutral
Aug 3, 2026
As of the latest report filing date, Sunshine Biopharma Inc. disclosed that recent sales of its common stock under a previously announced at-the-market offering triggered an adjustment to the terms of its outstanding Series B Warrants. The exercis...
Private Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Announces ATM Equity Sales Agreement
Neutral
Jul 20, 2026
On July 20, 2026, Sunshine Biopharma entered into an at-the-market issuance sales agreement with Aegis Capital Corp., allowing the company to sell up to $4 million of its common stock through Aegis as exclusive sales agent on Nasdaq or other exist...
Business Operations and StrategyLegal Proceedings
Sunshine Biopharma Settles Dispute With Former Nora President
Positive
Jul 10, 2026
On July 8, 2026, Sunshine Biopharma Inc. and its wholly-owned subsidiary Nora Pharma Inc. entered into a transaction and mutual release agreement with Nora’s former president, Malek Chamoun. Under the agreement, Sunshine Biopharma agreed to ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Approves Dilutive Share and Warrant Actions
Negative
May 29, 2026
On May 28, 2026, Sunshine Biopharma reported that majority stockholder and CEO Dr. Steve N. Slilaty approved, by written consent, the issuance of more than 20% of the company’s outstanding common shares at a discount to Nasdaq’s minimu...
Business Operations and StrategyPrivate Placements and Financing
Sunshine Biopharma Completes $6 Million Unit Offering
Positive
May 19, 2026
On May 18, 2026, Sunshine Biopharma Inc. entered into a placement agent agreement with Aegis Capital Corp. for a reasonable best‑efforts public offering of 12 million common or pre‑funded units, each including one share or pre‑fu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.